Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
an Outperform rating on Legend Biotech Corp (NASDAQ:LEGN) and set a $74 price target. The positive stance echoes the superior efficacy data on the company's multiple myeloma treatment CARVYKTI. Data presented at the ASH conference showed the candidate drug achieved more than 50 months of media progression-free survival in patients, setting a very high bar compared to peers. CARVYKTI is currently approved for adults with relapsed or refractory multiple myeloma, having treated over 9,000 patients globally. The investment firm insists the stock's current share price discounts the company's ability to maintain market share backed by a robust pipeline. Consequently, RBC Capital expects the company to continue enjoying strong growth and near-term profitability. That's in part because the company has demonstrated impressive revenue growth of 74.75% over the past 12 months. Legend Biotech Corporation (NASDAQ:LEGN) is a global, clinical-stage biotechnology company that develops and comme
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech (NASDAQ:LEGN) was given a new $50.00 price target on by analysts at Morgan Stanley.MarketBeat
- Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsightPR Newswire
- Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsightPR Newswire
- Legend Biotech (NASDAQ:LEGN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
LEGN
Sec Filings
- 12/8/25 - Form 6-K
- 11/17/25 - Form 144
- 11/12/25 - Form 6-K
- LEGN's page on the SEC website